Kiromic BioPharma (NASDAQ:KRBP – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, “Kiromic BioPharma Inc. is a discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with a therapeutic focus on […]
